Combinations of the cytokines IL-12, IL-2 and IFN-α significantly augment whereas the cytokine IL-4 suppresses the cytokine-induced antibody-dependent cellular cytotoxicity of monoclonal antibodies 17-1A and BR55-2

被引:12
作者
Flieger, D [1 ]
Spengler, U [1 ]
Beier, I [1 ]
Sauerbruch, T [1 ]
Schmidt-Wolf, I [1 ]
机构
[1] Univ Bonn, Med Klin & Poliklin 1, D-35105 Bonn, Germany
关键词
ADCC; cytokines; flow cytometry; monoclonal antibodies;
D O I
10.1006/cyto.1999.0610
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Since some cytokines effectively enhance the cytotoxicity of monoclonal antibodies, we investigated whether a combination of cytokines can augment the antibody-dependent cellular cytotoxicity (ADCC) of monoclonal antibodies 17-1A and BR55-2 against the colorectal carcinoma cell line HT29, Since monocytes/macrophages are important effector cells for ADCC, we used a new flow cytometric cytotoxicity assay, which allows the analysis of long-term-ADCC exerted by these cells. In our previous studies with peripheral blood mononuclear cells from normal donors, we found that IL-2, IL-12 and IFN-alpha increase ADCC, Therefore, we examined whether combination of these three cytokines with IL-2, IL-4, IL-6, IL-10, IL12, IFN-alpha, IFN-gamma, GM-CSF, M-CSF and TNF-alpha may yield higher ADCC than obtained by the application of single cytokines. Indeed, we found that the combinations IL-2/IFN-alpha, IL-2/IL-12 and IL-12/IFN-alpha potentiated ADCC. Interestingly, the ineffective single cytokines TNF-alpha and CM-CSF in the combinations IL-2/TNF-alpha, IFN-alpha/TNF-alpha and IFN-alpha/GM-CSF also proved to enhance ADCC. In contrast, IL-4 significantly suppressed the IL-2, IL-12 and IFN-alpha-induced ADCC, In addition, the immunosuppressive cytokine IL-10 in higher concentrations significantly suppressed the IL-12-induced-ADCC. Our results may be useful to find combinations of cytokines and mAb for the treatment of cancer. (C) 2000 Academic Press.
引用
收藏
页码:756 / 761
页数:6
相关论文
共 15 条
[1]   The combination of interleukin-2 and interferon α effectively augments the antibody-dependent cellular cytotoxicity of monoclonal antibodies 17-1A and BR55-2 against the colorectal carcinoma cell line HT29 [J].
Bungard, S ;
Flieger, D ;
Schweitzer, S ;
Sauerbruch, T ;
Spengler, U .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1998, 46 (04) :213-220
[2]  
EISENTHAL A, 1989, J IMMUNOL, V142, P2307
[3]   Enhancement of antibody dependent cellular cytotoxicity (ADCC) by combination of cytokines [J].
Flieger, D ;
Spengler, U ;
Beier, I ;
Kleinschmidt, R ;
Hoff, A ;
Varvenne, M ;
Sauerbruch, T ;
Schmidt-Wolf, I .
HYBRIDOMA, 1999, 18 (01) :63-68
[4]   A NOVEL NONRADIOACTIVE CELLULAR CYTOTOXICITY TEST BASED ON THE DIFFERENTIAL-ASSESSMENT OF LIVING AND KILLED TARGET AND EFFECTOR-CELLS [J].
FLIEGER, D ;
GRUBER, R ;
SCHLIMOK, G ;
REITER, C ;
PANTEL, K ;
RIETHMULLER, G .
JOURNAL OF IMMUNOLOGICAL METHODS, 1995, 180 (01) :1-13
[5]   GRANULOCYTE-MONOCYTE COLONY-STIMULATING-FACTOR AUGMENTS THE INTERLEUKIN-2-INDUCED CYTOTOXIC ACTIVITY OF HUMAN-LYMPHOCYTES IN THE ABSENCE AND PRESENCE OF MOUSE OR CHIMERIC MONOCLONAL-ANTIBODIES (MAB 17-1A) [J].
MASUCCI, G ;
RAGNHAMMAR, P ;
WERSALL, P ;
MELLSTEDT, H .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1990, 31 (04) :231-235
[6]   ANTIBODY-DEPENDENT ANTITUMOR CYTO-TOXICITY BY HUMAN-MONOCYTES CULTURED WITH RECOMBINANT MACROPHAGE COLONY-STIMULATING FACTOR - INDUCTION OF EFFICIENT ANTIBODY-MEDIATED ANTITUMOR CYTO-TOXICITY NOT DETECTED BY ISOTOPE RELEASE ASSAYS [J].
MUNN, DH ;
CHEUNG, NKV .
JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 170 (02) :511-526
[7]   CYTOTOXICITY OF WHITE BLOOD-CELLS ACTIVATED BY GRANULOCYTE-COLONY-STIMULATING FACTOR, GRANULOCYTE/MACROPHAGE-COLONY-STIMULATING FACTOR AND MACROPHAGE-COLONY-STIMULATING FACTOR AGAINST TUMOR-CELLS IN THE PRESENCE OF VARIOUS MONOCLONAL-ANTIBODIES [J].
RAGNHAMMAR, P ;
FRODIN, JE ;
TROTTA, PP ;
MELLSTEDT, H .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1994, 39 (04) :254-262
[8]   ROLE OF INTERLEUKIN-2, INTERLEUKIN-4, AND ALPHA-INTERFERON, BETA-INTERFERON, AND GAMMA-INTERFERON IN STIMULATING MACROPHAGE ANTIBODY-DEPENDENT TUMORICIDAL ACTIVITY [J].
RALPH, P ;
NAKOINZ, I ;
RENNICK, D .
JOURNAL OF EXPERIMENTAL MEDICINE, 1988, 167 (02) :712-717
[9]   Interleukin-12 increases bispecific-antibody-mediated natural killer cell cytotoxicity against human tumors [J].
Sahin, U ;
KraftBauer, S ;
Ohnesorge, S ;
Pfreundschuh, M ;
Renner, C .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1996, 42 (01) :9-14
[10]  
Sondel PM, 1997, CANCER J SCI AM, V3, pS121